PVI
LOGC

Pura Vida Investments’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Pura Vida Investments’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-230,121
Closed -$532K – 314
2021
Q4 		$532K Sell
230,121
-15,371
-6% -$52K 0.02% 210
2021
Q3 		$1.12M Sell
245,492
-3,764
-2% -$16.6K 0.03% 214
2021
Q2 		$1.11M Sell
249,256
-3,846
-2% -$19.6K 0.03% 177
2021
Q1 		$1.84M Buy
253,102
+3,102
+1% +$25.5K 0.05% 166
2020
Q4 		$1.91M Buy
+250,000
New +$1.67M 0.07% 146

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.47B AUM 42.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Pura Vida Investments's LOGC Position: Q1 2022 in Review

Pura Vida Investments sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 230,121 shares — an estimated $532K sold.

Pura Vida Investments first reported a position in LOGC in Q4 2020 and held it in 5 quarters. The position peaked at $1.91M in Q4 2020. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

  • Pura Vida Investments reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Pura Vida Investments sold 230,121 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $532K.
  • Pura Vida Investments first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Pura Vida Investments's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.91M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.